Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aecom (ACM) vs Eli Lilly And Co (LLY) Price & Performance

Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Aecom vs Eli Lilly And Co — how do they compare? Aecom trades at $62.29 (market cap $8.62B), while Eli Lilly And Co trades at $1,216.31 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 125.3× Aecom's market cap, and Aecom pays the higher dividend (1.77%). Which is the better fit depends on your goals.

ACMLLY
Market Cap
$8.62B$1.08T
Sector
IndustrialsHealth
52-Week High
$134.35$1.24K
52-Week Low
$66.86$639.43
Enterprise Value
$10.81B$1.13T
Dividend Yield
1.77%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aecom

ACM's stock is trading at $73.30, down 3.35% in the last session, reflecting negative momentum after a Q2 2026 earnings miss. The technical outlook is bearish, with support at $72 and resistance at $76. Fundamentally, revenue reached $16.14 billion in 2025, but net income margin is thin at 1.87%, and ROE is negative. Recent news includes a securities investigation announcement and a large project charge impacting earnings.

The investment outlook is mixed: analyst consensus is bullish with a $88.25 price target, but risks include earnings volatility, a fraud probe, and rising debt-to-asset ratio. Opportunities lie in record backlog growth and new project wins like the Lisbon airport design. Investors should weigh strong institutional support against operational and legal headwinds.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aecom

Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.

Read more on ACM

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY